High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial

by Martin J Boeree, Norbert Heinrich, Rob Aarnoutse et al.
Lancet Infect Dis 2016, Published Online: October 26, 2016

11 pp. 301 kB

Tuberculosis is the world’s leading infectious disease killer. The authors aimed to identify shorter, safer drug regimens for the treatment of tuberculosis. They conclude that a dose of 35 mg/kg rifampicin was safe, reduced the time to culture conversion in liquid media, and could be a promising component of future, shorter regimens. Their adaptive trial design was successfully implemented in a multi-centre, high tuberculosis burden setting, and could speed regimen development at reduced cost.

(Visited 45 times, 1 visits today)
This entry was posted in Essential Medicines, General, Tuberculosis. Bookmark the permalink.